Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arovella Therapeutics Limited ( (AU:ALA) ) has provided an announcement.
Arovella Therapeutics Limited has reported significant progress in its third quarter of FY25, with a cash reserve of $23.5 million and a successful $15 million placement to fund the phase 1 trial of its lead product, ALA-101. The company has also transferred its manufacturing process into a cGMP environment and completed key IND-enabling studies, positioning itself well for upcoming clinical trials and further expansion of its iNKT cell therapy platform.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited is a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform. The company is engaged in advancing its lead product, ALA-101, targeting CD19-positive blood cancers, and developing solid tumor programs, particularly in gastric cancer.
YTD Price Performance: -52.94%
Average Trading Volume: 2,592,817
Technical Sentiment Signal: Buy
Current Market Cap: A$94.71M
See more data about ALA stock on TipRanks’ Stock Analysis page.